Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) insider Jennifer Michaelson sold 8,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $15.64, for a total value of $125,120.00. Following the sale, the insider now owns 107,942 shares in the company, valued at approximately $1,688,212.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jennifer Michaelson also recently made the following trade(s):

• On Thursday, September 5th, Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $18.09, for a total value of $144,720.00.

Cullinan Therapeutics Stock Up 2.8 %

Shares of NASDAQ CGEM opened at $16.02 on Friday. The stock has a market cap of $928.84 million, a PE ratio of -5.24 and a beta of -0.12. Cullinan Therapeutics, Inc. has a 52-week low of $7.64 and a 52-week high of $30.19. The business has a 50-day moving average price of $16.83 and a 200 day moving average price of $19.11.

Cullinan Therapeutics (NASDAQ:CGEM) last announced its earnings results on Thursday, August 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). Sell-side analysts anticipate that Cullinan Therapeutics, Inc. will post -3.2 earnings per share for the current year.

Institutional Trading of Cullinan Therapeutics

A number of large investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. lifted its position in Cullinan Therapeutics by 31.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,599 shares of the company’s stock worth $44,000 after acquiring an additional 615 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Cullinan Therapeutics by 3.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,842 shares of the company’s stock worth $390,000 after acquiring an additional 820 shares during the period. Amalgamated Bank lifted its position in Cullinan Therapeutics by 97.3% during the 3rd quarter. Amalgamated Bank now owns 1,768 shares of the company’s stock worth $30,000 after acquiring an additional 872 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Cullinan Therapeutics by 22.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,269 shares of the company’s stock worth $294,000 after acquiring an additional 3,134 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Cullinan Therapeutics by 73.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,883 shares of the company’s stock worth $155,000 after acquiring an additional 3,758 shares during the period. 86.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CGEM. Wedbush reiterated an “outperform” rating and issued a $36.00 price objective on shares of Cullinan Therapeutics in a report on Wednesday, September 18th. UBS Group began coverage on Cullinan Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $30.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $28.00 price objective on shares of Cullinan Therapeutics in a report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Cullinan Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $31.67.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.